BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.
CDC Afrique est préoccupé par les informations inexactes distribués par les médias traditionnels et sociaux en ce qui concerne la prévention et le traitement des maladies nouvelles coronavirus (Covid-19).
Sur la base d’un examen des preuves et de l’évaluation d’experts, le CDC Afrique r...ecommande
more
The Africa Centres for Disease Control and Prevention (Africa CDC) is concerned about inaccurate information being distributed through traditional and social media regarding prevention and treatment of novel coronavirus disease (COVID-19).
Report the Abuse fact sheet
20 Mart 2020
http://www.covid19-druginteractions.org
Çeviren:
Kamu Hastaneleri Genel Müdürlüğü
Tedarik Planlama, Stok ve Lojistik Yönetimi Daire Başkanlığı Hastane Eczacılığı Yönetim Birimi
Boniface Dongmo-Nguimfack WHO/HIV/SIP
08. March 2016
. MSF Essential Drugs Guidelines دليل عملي موجه للأطباء والصيادلة والممرضين والمساعدين الطبيين
Medicines and medical devices for 10 000 people for approximately three months
Руководство представляет информацию о процедурах диагностики, порядке формирования схем лечения, осуществления клинического мониторинга эффективности и безопа...ности лечения на уровне пилотных районов, а также проведение программной оценки реализации краткосрочных схем и новых препаратов для лечения больных с М/ШЛУ-ТБ в условиях Таджикистана.
more